title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Time-series assessment of function | hypermobility | Qualitative visual evaluation of the kinematic and kinetic time-series plots showed some differences between joint hypermobility and non-joint hypermobility participants. The joint hypermobility group demonstrated greater hip flexion than the non-joint hypermobility group throughout the entire DVJ (Fig. Kinematic time-... | PMC10626644 | |
Discussion | hypermobility, decreased joint stiffness, chronic musculoskeletal pain, pain, joint hypermobility, chronic pain | CHRONIC PAIN, SECONDARY | The results of this pilot study suggest that adolescents with JFM and joint hypermobility show similar clinical pain intensity levels to those with JFM without joint hypermobility; however, those with joint hypermobility had lower levels of overall physical impairment. We found small differences in biomechanics between... | PMC10626644 |
Conclusion | joint hypermobility, hypermobility, chronic musculoskeletal pain | These results tentatively support the use of neuromuscular training and exercise programming in adolescents with chronic musculoskeletal pain, regardless of joint hypermobility status; though, additional work is needed to address concerns regarding our study findings being attributed to error alone. However, findings a... | PMC10626644 | |
Acknowledgements | No acknowledgments of note beyond the study team. | PMC10626644 | ||
Financial disclosure | Other than disclosed funding (see below), the authors have no other financial disclosures in relation to this study. | PMC10626644 | ||
Author’s contributions | CAD, MP, GDM | GDM, CAD | All authors contributed to this manuscript. WRB, LAW, CAD, and SKZ contributed a majority of the writing of this manuscript, while ST, MP, KK, TVT, SEW, and GDM provided expert-informed modifications and edits to the text. CAD, ST, KK, and GDM conducted and analyzed biomechanical data, and provided expert feedback and ... | PMC10626644 |
Funding | Arthritis, Musculoskeletal | ARTHRITIS, SKIN DISEASES | This study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), R21AR063412 and K24AR056687 to the last author (SKZ). Funding source R21AR063412 provided support for SKZ to design the study, staff support for data collection, analysis, and manuscript writing. Funding source K... | PMC10626644 |
Availability of data and materials | Given the size and complexity of the biomechanics files, data may be provided and shared upon a reasonable request. | PMC10626644 | ||
Declarations | PMC10626644 | |||
Ethics approval and consent to participate | This study was approved by the Institutional Review Board at Cincinnati Children’s Hospital and Medical Center. Written informed consent was obtained by parents/guardians and written assent from participants. | PMC10626644 | ||
Consent for publication | No individual consent for publication is required for this study. | PMC10626644 | ||
Competing interests | The authors have no financial disclosures or competing interests to report relevant to this study. | PMC10626644 | ||
References | PMC10626644 | |||
Keywords | PMC10570009 | |||
Abbreviations: | differencetype-2 diabetes | VASODILATION | Akt substrate 160 kDacapillaries per individual fibrecapillary contactscapillary-to-fibre-perimeter exchangeconfidence limitsnon-protein isocaloric controlcytochrome citrate synthaseendothelial nitric oxide synthaseglucose clearance rateglucose transporter 4glutathioneglutathione disulphideglutathione peroxidase 1insul... | PMC10570009 |
Introduction | We recently developed a novel edible keratin-derived protein (KDP) containing uniquely high concentrations of cysteine, glycine, and arginine [Glutathione is part of the thiol/disulfide system centred around the selenium-containing glutathione peroxidases (GPx) and thiol reductases, which in conjunction with peroxide s... | PMC10570009 | ||
Materials and Methods | T2DM | Men and women with T2DM (n = 35; see Results section for cohort descriptive statistics) completed a 14-wk placebo-controlled randomised trial comprising standardised exercise 5 d/wk and 2×20 g protein/d dietary supplementation in three arms: KDP-whey blend (KDPWHE), whey (WHEY), non-protein isocaloric control (CON). Th... | PMC10570009 | |
Preparation, analysis and reducing potential of the keratin-derived protein (KDP) and whey protein isolate | PMC10570009 | |||
Preparation of KDP isolate | HEAT | Double-scoured wool (Wool Services International, Christchurch, New Zealand) was solubilized and degraded for nutritional application using a novel process in which a reaction mixture was formed containing food grade citric acid (90 mM) and ascorbic acid (6 mM) at pH 2.3. Ascorbic acid acts as a stabilizing and reducin... | PMC10570009 | |
Proximate analysis of KDP and WHEY | SEPARATION, ASH, TAG | Proximate analysis was carried out according to the 1990 Association of Official Analytical Chemists methods. Amino acids were analysed in triplicate with a standard hydrochloric acid hydrolysis followed by RP HPLC separation using AccQ Tag derivatization. Cysteine/methionine were analysed using performic acid oxidatio... | PMC10570009 | |
Protein extraction and solubilization of KDP and WHEY | Dried dietary protein powder (10 mg) of KDP and WHEY were extracted overnight by rotation (Mini Labroller, Labnet International Inc) at room temperature in 1 ml of extraction buffer (8 mM urea, 0.05 M Tris, 50 mM TCEP, pH 4). Extracted protein was spun down at 3000 g for 5 min and the absorbance of the supernatant was ... | PMC10570009 | ||
Reduction potential of KDP and WHEY | The accessible thiol content was determined in KDP and WHEY to assess the reduction potential. The proteins were extracted, and the diluted protein solutions were assayed by reaction with monobromobimane (MBB) and comparison to a GSH standard curve. 1 mM GSH (in 1 mM TCEP, 2.7 mM KCl, 0.14 M NaCl, 8 mM Na | PMC10570009 | ||
Human trial | PMC10570009 | |||
Participants | T2DM | MAY | Males and females of any ethnicity diagnosed with T2DM were recruited at medical centres and from the local community in Wellington (New Zealand) from January 2016 to January 2017 with final testing in May 2017. Inclusion criteria were non-insulin dependent T2DM for > one year (HbA | PMC10570009 |
Study design | The study was a multi-arm, double-blind, parallel group, randomized controlled trial comprising 14 wk of standardized exercise combined with dietary protein supplementation conducted in University and Hospital gyms, labs, and clinics. Participants all completed the same controlled exercise regimen and were randomized t... | PMC10570009 | ||
Dietary protein intervention | gluten free flour) | Protein treatments were a non-protein isocaloric placebo control (CON, blend of 50% maltodextrin and 50% low protein gluten free flour); isoenergetic whey protein isolate as active control (WHEY, 40 g WPI-A895; Fonterra, New Zealand), or a blend of KDP isolate and whey protein isolate (KDPWHE, 17 g KDP+23 g whey protei... | PMC10570009 | |
Hyperinsulinemic-isoglycaemic clamp | INSULIN SENSITIVITY | Participants underwent a 2-h hyperinsulinaemic-isoglycaemic clamp at weeks 0 and 15 after an overnight fast. Using dietary recall, the diet was equal the day before the clamps, and participants were provided with 250-300 ml of water in the morning prior to procedures. The post-intervention clamp was performed 46-50 h a... | PMC10570009 | |
Skeletal muscle blood flow and vasodilation | VASODILATION | Basal and insulin-stimulated skeletal muscle blood flow (mBF) and vasodilation (blood volume, mBV) were measured during the clamp using continuous-wave near infrared spectroscopy (NIRS) [The measurements were performed before obtaining the muscle biopsies, and great care was taken to ensure that the participants lay st... | PMC10570009 | |
Skeletal muscle and erythrocyte collection and analysis | Skeletal muscle, ∼100 mg frozen weight) from | Skeletal muscle tissue (∼100 mg frozen weight) from | PMC10570009 | |
Blood analysis | Samples for HbA | PMC10570009 | ||
Immunofluorescence protocol | SECONDARY, -20 | Samples were cut at 7 μm in transverse orientation using a microtome cryostat at -20 °C (Leica CM1850, Wetzlar, Germany). Sections were mounted on superfrost microscope slides (Sigma-Aldrich, catalogue #Z692255), then air-dried for 1 h. Slides were then either stored at -80 °C, or transferred straight into 1 × TBS, pH ... | PMC10570009 | |
Image capture | Images of immunostained muscle fibres were captured using a Spot-RT slider (SPOT Imaging Solutions: Diagnostic Instruments, Inc., Sterling Heights, MI) cooled digital microscope camera mounted on a compound widefield fluorescence microscope (Olympus BX-50, Olympus Corporation, Tokyo, Japan) equipped with a CoolLED illu... | PMC10570009 | ||
Image analysis | Three images per sample were taken and Image J (National Institutes of Health, Bethesda, MD) was utilized for analysis. GLUT4 translocation with the plasma membrane was measured as the mean grey value within the plasma membrane region, which was determined by masking the dystrophin-positive area [ | PMC10570009 | ||
Preparation of skeletal muscle tissue samples for biochemical and Western blot analyses | COLD | For GSH/GSSG and oxiPRX2/3, muscle tissue proteins were extracted as adapted from Kumar et al. [For Western blot analyses of NRF2, GPx1, SOD1, Akt, AS160, and PAK1/2, 30 mg of snap-frozen muscle tissue was homogenized in ice cold RIPA buffer (15 mM Tris, 167 mM NaCl, 0.5% sodium, deoxycholate, 0.1% SDS, 1% Triton X-100... | PMC10570009 | |
Preparation of erythrocytes for GSH/GSSG analysis and SDS-electrophoresis | LYSED | Frozen packed erythrocytes treated with NEM, were lysed with 270 μl deionized water, vortexed and split into three parts for further analysis. For analysis of GSH/GSSG, 200 μl of lysate was mixed with 300 μl of precipitation solution to denature the proteins (5.37 mM EDTA, 5.13 M NaCl, and 0.17 M orthophosphoric acid).... | PMC10570009 | |
GSH/GSSG analysis | GSH (as its NEM derivative) and GSSG were analysed by liquid chromatography tandem mass spectrometry as adapted from Harwood et al. [ | PMC10570009 | ||
Western blot protocols | Protein extracts from skeletal muscle (4 μg for PRX2/3) and erythrocytes (6 μg for PRX2) were separated by SDS-PAGE under non-reducing conditions. Extracts from skeletal muscle (30 μg for NRF2, GPx1, SOD1 or 40 μg for Akt, AS160, and PAK1/2) were separated by SDS-PAGE under reducing conditions. Separated proteins were ... | PMC10570009 | ||
Nuclear factor kappa light chain enhancer of activated B cells (NF-κB) p50/p65 DNA-binding assay in skeletal muscle nuclear extract | The nuclear fraction was isolated using a Nuclear Extraction kit (ab113474, Abcam) and the DNA-binding activity of p65 and p50 NF-κB subunits in the lysates was evaluated by colorimetric enzyme-linked immunosorbent assay (ELISA) using the NF-κB Transcription Factor Assay kit (ab207216, Abcam), according to the manufact... | PMC10570009 | ||
Body composition, cardiometabolic risk factors, physical performance, daily physical activity level and gastrointestinal symptoms questionnaire | nausea, belching, diarrhoea, flatulence, Diabetes | DIABETES | Fat and fat-free mass were measured using bioelectrical impedance (Bodystat 1500 analyzer, UK) on the morning of the hyperinsulinaemic-isoglycaemic clamp. Waist circumference was measured at baseline and again prior to the final exercise session according to the International Diabetes Federation. Systolic and diastolic... | PMC10570009 |
Exercise procedures | In the morning after an overnight fast and rest day, peak power (PP) was established using cycle ergometry (Velotron, WA) with resistance increasing 1 W/3 s until exhaustion [ | PMC10570009 | ||
Statistical analysis | PMC10570009 | |||
Sample size | Sample size was calculated [ | PMC10570009 | ||
General statistical method | Data were analysed using mixed model longitudinal analysis of covariance for change scores adjusted for the baseline value [Thresholds for interpreting the magnitude of effect sizes (relative to clinical thresholds or the standardized difference/Glass's Baseline characteristics of the participants who completed the cli... | PMC10570009 | ||
Results | PMC10570009 | |||
Protein and supplement composition | The macronutrient and amino acid composition of the KDP and WHEY protein isolates, and supplement composition are in SM | PMC10570009 | ||
Participant disposition, gastrointestinal symptoms, and supplement acceptability | Of the 43 randomized participants, 35 completed (8 dropouts, 19%) (see Consort flow diagram | PMC10570009 | ||
Glucose clearance, nutrient delivery, and sarcoplasmic GLUT4 translocation | Skeletal muscle microvascular, type-2 diabetes mellitus, skeletal muscle microvascular blood flow | INS | In response to insulin stimulation (hyperinsulinaemic-isoglycaemic clamp), there was good and very good evidence for substantial (moderate standardized effect size) increases in whole-body glucose clearance rate (GCR) and skeletal muscle microvascular blood flow (mBF), respectively, and for good evidence for moderate i... | PMC10570009 |
Discussion | hormesis, T2DM | INSULIN RESISTANCE, INSULIN SENSITIVITY | There was good evidence to suggest that the ingestion of the cysteine-rich keratin-derived combinatorial protein blend (KDPWHE) for 14 weeks by adults with T2DM produced a clinically relevant increase in whole-body glucose clearance rate (GCR), relative to a non-protein placebo control (CON), based on the mean effect s... | PMC10570009 |
Conclusions | death, T2DM | CARDIOVASCULAR DISEASE, INSULIN SENSITIVITY | The pilot trial provided good evidence to suggest that chronic dietary supplementation with a novel cysteine-rich keratin protein blend may produce a clinically-relevant improvement in whole-body glucose clearance and aspects of muscle insulin sensitivity in humans with T2DM. These changes were associated within good e... | PMC10570009 |
Funding disclosure | Ministry of Business, Innovation and Employment, NZ [UOOX1404]; Wool Industrial Research Ltd, NZ. | PMC10570009 | ||
CRediT authorship contribution statement | Peeters, WM: Conceptualization, Data curation, Investigation, Project administration, Writing - original draft, review & editing, revisions. Gram, M: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing - original draft, review & editing. Dias, GJ: Conceptualiza... | PMC10570009 | ||
Declaration of competing interest | We were unable to get the Elsevier online DOI working, so this document covers declarations.George Dias, David Rowlands, and Margreet Vissers received a grant to conduct the study from the New Zealand Ministry of Ministry of Business, Innovation and Employment, NZ [UOOX1404].David Rowlands received additional funding f... | PMC10570009 | ||
References | PMC10570009 | |||
Supplementary data | The following are the Supplementary data to this article: | PMC10570009 | ||
SM Fig. 1 | CONSORT style summary of participant flow through the trial. | PMC10570009 | ||
SM Fig. 2 | Effect of keratin-derived protein on measures of skeletal muscle capillarization. | PMC10570009 | ||
SM Fig. 3 | Representative widefield images of skeletal muscle eNOS, p-eNOS | PMC10570009 | ||
Acknowledgements | Shanggari Venugopal, Brandon Woolley, William Pickup, Stephanie Bozonet, Adam Lucero, Henry Jones. The participants.Supplementary data to this article can be found online at | PMC10570009 | ||
Amendments from Version 1 | INFILTRATION | [version 2; peer review: 1 approvedNo competing interests were disclosed.
This revised article features notable improvements. The title has been refined to "Ketamine infiltration improves analgesia after thyroid surgery," accurately encapsulating the essence of the study. Methodologically, difficult airways were co... | PMC10835105 | |
Introduction | postoperative pain | THYROID, INFILTRATION | Thyroid surgery is known to be responsible for mild to moderate postoperative pain during the first 24 hours after surgery.
Ketamine has a high affinity for N-methyl-D-aspartate receptors; it can also bind to opioid mu and sigma receptors that provide central and peripheral analgesic effects.
The purpose of this study ... | PMC10835105 |
Methods | PMC10835105 | |||
Selection of patients, ethical approval and consent | allergic reactions, allergy, cardiac or respiratory disease, unstable diabetes | BLEEDING, ALLERGY, ALLERGIC REACTION, COMPLICATIONS | Ethical approval for this study was given by the Committee for the Protection of People in Southern Tunisia (approval number 0117/18). This randomized double-blind study was achieved through collaboration between the ENT department and the anesthesia department of the university hospital, Habib Bourguiba in Sfax, Tunis... | PMC10835105 |
The patients and randomization | postoperative pain, pain | The patients were informed about the anesthetic protocols and were educated about the use of the visual analog scale (VAS) to evaluate the severity of the pain. All patients in the study were blinded to the drug they received for postoperative pain.The patients were randomly assigned to the following two groups using a... | PMC10835105 | |
General anesthesia procedure | STERILE, INFILTRATION, INFILTRATING | After 3 minutes of preoxygenation, anesthesia was induced with an injection of 3 μg/kg of Fentanyl followed by 3 mg/kg of Propofol; and with intubation using a silicone wire-reinforced tracheal tube with 0.2 mg/kg Cisatracurium. Anesthesia was maintained using isoflurane with a minimum alveolar concentration (MAC) of 1... | PMC10835105 | |
Analgesic protocol | Thirty minutes before the end of the surgery, all patients received 1 g of paracetamol ad then were extubated before being moved to the post-anesthetic care unit (PACU) for close monitoring for 2 hours. In the PACU, intravenous morphine titration (2 mg every 5 min) was performed until the VAS value was less than 30. Al... | PMC10835105 | ||
Evaluation criteria | pain | The primary outcomes were to determine the intensity of the pain using VAS from 0-100 in the first 24 hours. The VAS score was assessed every 10 minutes in the PACU for 2 hours and every 6 hours during the first 24 hours after the operation in the ENT department. Nefopam was administered in the cases where VAS exceeded... | PMC10835105 | |
Statistical analysis | In each group, a total number of 27 patients was required to obtain a difference on the VAS scale of 20 mm (standard deviation of 25 mm), with a power of 0.9 and an α=0.05. To allow for some margin of error in the underlying assumptions, the baseline sample size was increased by 10 % to 32 patients per group. χ
| PMC10835105 | ||
Results | PMC10835105 | |||
Study population | The study lasted for a total of 6 months from September 2018 to March 2019. Sixty-four patients were included. Two patients were withdrawn from the study for prolonged surgery (more than 3 hours). The flow of patients is represented in the CONSORT diagram of the study, which is shown in
| PMC10835105 | ||
CONSORT 2010 flow chart for the patients in the study. | PMC10835105 | |||
Demographic characteristics and intraoperative anesthetic characteristics of both groups. | Values are mean±standard deviation.S: physiological serum, K: ketamine, cm: centimeters, kg: kilograms, HR: heartbeat, bpm: beats per minute, SBP: systolic blood pressure, MAP: mean arterial pressure, DBP: diastolic blood pressure, SpO
Student t-test.Fisher exact test.χ
| PMC10835105 | ||
Assessment of postoperative pain | Pain | Pain scores during swallowing were significantly lower for group K in the PACU at 0, 10, and 20 minutes (
| PMC10835105 | |
Mean VAS values in group S and group K at rest and during swallowing in the PACU admission period. | Group S: saline solution group, group K: ketamine group, VAS: visual analog scale, PACU: post anesthetic care unit.Regarding the first 24-hour postoperative hospitalization period in the ENT department, the mean VAS values were higher in group S compared to group K; either at rest or during swallowing, but the differen... | PMC10835105 | ||
Mean VAS values in group S and group K at rest and during swallowing in the first 24 hours postoperatively. | Dizziness, Respiratory distress, vomiting, hallucinations, Nausea, hematoma | HEMATOMA | Group S: saline solution group, Group K: ketamine group, VAS: visual analog scale.None of the patients in group K received morphine while it was administered to four patients in group S. The mean morphine consumption in the PACU was 0.71 mg and 0 mg respectively in group S and group K. The difference in morphine consum... | PMC10835105 |
Discussion | cleft palate, postoperative pain, pain, respiratory distress, nausea, vomiting | INFILTRATE, THYROID, INFILTRATION, INFILTRATING | Acute pain is one of the most common complaints after surgery. Thyroid surgery is known to be responsible for mild to moderate postoperative pain during the first 24 hours, with a mean VAS score of 6.9 (±1.7).
The attempted locoregional anesthetic approaches to reduce post-thyroidectomy pain have included mainly bilate... | PMC10835105 |
Conclusions | INFILTRATION | In conclusion, local wound infiltration using 2 mg/kg of ketamine is an effective approach to reduce opioid requirements after thyroid surgery without increasing the side effects of ketamine. | PMC10835105 | |
Acknowledgments | We would like to thank all nurses and the personnel of the operating unit, in the otolaryngology and anesthesiology departments for their assistance and cooperation. | PMC10835105 | ||
Data availability | PMC10835105 | |||
Underlying data | INFILTRATION | Figshare: Underlying data for ‘Ketamine infiltration decreases opioid requirement after thyroid surgery’,
This project contains the following underlying data:
data ketamine thyroidectomy.sav (SPSS format; all datasets have been de-identified in accordance with the Safe Harbor method)CONSORT checklist
Data are available... | PMC10835105 | |
References | Postoperative pain, hallucinations, tachycardia, pain | SAID |
1. The study design: - Random grouping is unequal: The proportion of patients undergoing total thyroidectomy or partial thyroidectomy is much different between the two groups. Different types of surgery result in different level of pain. It make great influence on research results. - The post-operative pain relief des... | PMC10835105 |
References | Postoperative pain, postoperative pain, pain | ADVERSE EFFECTS, INFILTRATION |
Title:
Postoperative opioid requirements were assessed only in the PACU. Postoperative pain is your primary outcome. Please rephrase your title. Methods:
Difficult airways should be considered as an exclusion criteria because you had assessed VAS during swallowing.Please precisely include which ketamine concentrati... | PMC10835105 |
Objective | knee arthroplasty, TKA | Academic Editor: Vahid Rakhshan The purpose of the present study (a randomized clinical trial) was to evaluate the preemptive analgesic effects of pregabalin combined with celecoxib in total knee arthroplasty (TKA). | PMC9851777 | |
Methods | From January 2019 to June 2021, we enrolled 149 patients who underwent TKA and divided them into four groups: the placebo group ( | PMC9851777 | ||
Results | pain | The pain scores upon movement were significantly lower in the combination group than in the other three groups at 6, 12, 24, and 48 hours after surgery ( | PMC9851777 | |
Conclusion | pain | The preemptive analgesia regimen of pregabalin combined with celecoxib had positive effects on improving acute pain and reducing the cumulative dose of opioids after TKA. This trial is registered with | PMC9851777 | |
1. Introduction | postoperative pain, inflammation, pain, knee arthroplasty, TKA, trauma | ADVERSE EFFECTS, INFLAMMATION, KNEE OSTEOARTHRITIS | Total knee arthroplasty (TKA), a surgical method for the treatment of terminal stage knee osteoarthritis, can effectively relieve pain and restore knee function. However, patients experience moderate to severe pain after TKA. Acute pain after TKA can have a negative effect on enhanced recovery after surgery among patie... | PMC9851777 |
2. Materials and Methods | PMC9851777 | |||
2.1. Ethical Approval | The present study was a double-blind randomized clinical trial and was conducted in the affiliated hospital of our university. The study was approved by the ethics committee of the affiliated hospital of our university and conducted in accordance with the Declaration of Helsinki. In addition, the study was retrospectiv... | PMC9851777 | ||
2.2. Inclusion and Exclusion Criteria | mental illness, allergy, cognitive impairment, liver and kidney insufficiency | ALLERGY, CARDIOPULMONARY DISEASE, DIGESTIVE TRACT DISEASE | From January 2019 to June 2021, 201 patients who underwent TKA were subjected to a strict eligibility review. The inclusion criteria were as follows: patients who received elective, initial, and single TKA. The exclusion criteria were as follows: (1) patients with an American Society of Anesthesiologists (ASA) classifi... | PMC9851777 |
2.3. Design and Conduct of the Study | postoperative nausea and vomiting, pain, dizziness, PONV, urinary retention | INFILTRATION, DEEP VEIN THROMBOSIS (DVT), ADVERSE EFFECTS, GASTROINTESTINAL HEMORRHAGE, COMPLICATIONS | Pregabalin and celecoxib are produced by Pfizer in the United States under the trade names Lyrica and Celebrex, respectively. Pregabalin, celecoxib, and the placebo were packaged in the same opaque packaging by the University Hospital Health Research Center pharmacy. The placebo capsule contained a mixture of 50% cellu... | PMC9851777 |
2.4. Statistical Analysis | Power analysis was performed based on the data from a previous study [ | PMC9851777 | ||
3. Results | vomiting reaction | A total of 160 patients were enrolled in the study, 7 patients discontinued PCIA because of severe vomiting reaction to sufentanil. 2 patients asked to withdraw from the study and 2 patients were suspended surgery. Consequently, 149 patients were included in the final data analysis. The CONSORT study participant flow d... | PMC9851777 | |
3.1. Patient and Surgical Characteristics | There were no significant differences in the patient and surgical characteristics among the four groups ( | PMC9851777 | ||
3.2. VAS Pain Scores and the Cumulative Dose of Sufentanil | As shown in | PMC9851777 | ||
3.3. hs-CRP Level, Knee Function Indicator, and Incidence of Postoperative Complications | As shown in | PMC9851777 | ||
3.4. Linear Regression Analysis | pain | REGRESSION | In the linear regression analysis, the mean pain score upon movement within 48 hours after surgery (4.78 ± 1.02) was the independent variable ( | PMC9851777 |
4. Discussion | postoperative pain, nausea and vomiting, pain, urinary retention, TKA, drug dependence | CHRONIC PAIN, RESPIRATORY DEPRESSION, POSTOPERATIVE COMPLICATIONS | Perioperative pain management is key to the smooth implementation of enhanced recovery after surgery (ERAS), which has rapidly become a popular concept in the field of orthopedics. Although the combined application of various postoperative analgesia methods can improve the postoperative acute pain of TKA patients, many... | PMC9851777 |
5. Conclusion | pain | The preemptive analgesia regimen of pregabalin combined with celecoxib had positive effects on improving acute pain and reducing the cumulative dose of opioids after TKA. | PMC9851777 | |
Acknowledgments | The authors thank the trial patients and the trial site personnel who assisted with the trial. | PMC9851777 | ||
Data Availability | The data used to support the findings of this study are available from the corresponding author upon request. | PMC9851777 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.